These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30968338)

  • 21. Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing's disease: interim results from a long-term real-world evidence study.
    Manetti L; Deutschbein T; Schopohl J; Yuen KCJ; Roughton M; Kriemler-Krahn U; Tauchmanova L; Maamari R; Giordano C
    Pituitary; 2019 Oct; 22(5):542-551. PubMed ID: 31440946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease.
    Webb SM; Ware JE; Forsythe A; Yang M; Badia X; Nelson LM; Signorovitch JE; McLeod L; Maldonado M; Zgliczynski W; de Block C; Portocarrero-Ortiz L; Gadelha M
    Eur J Endocrinol; 2014 Jul; 171(1):89-98. PubMed ID: 24760537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide.
    Reznik Y; Bertherat J; Borson-Chazot F; Brue T; Chanson P; Cortet-Rudelli C; Delemer B; Tabarin A; Bisot-Locard S; Vergès B
    Diabetes Metab; 2013 Feb; 39(1):34-41. PubMed ID: 23228667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide.
    Cannavo S; Messina E; Albani A; Ferrau F; Barresi V; Priola S; Esposito F; Angileri F
    Endocrine; 2016 Jun; 52(3):481-7. PubMed ID: 25877016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pasireotide: a review of its use in Cushing's disease.
    McKeage K
    Drugs; 2013 May; 73(6):563-74. PubMed ID: 23605695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide.
    Guarnotta V; Pizzolanti G; Ciresi A; Giordano C
    J Endocrinol Invest; 2018 Oct; 41(10):1137-1147. PubMed ID: 29396758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease.
    Newell-Price J; Pivonello R; Tabarin A; Fleseriu M; Witek P; Gadelha MR; Petersenn S; Tauchmanova L; Ravichandran S; Gupta P; Lacroix A; Biller BMK
    Eur J Endocrinol; 2020 Feb; 182(2):207-217. PubMed ID: 31804965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease.
    Barbot M; Guarnotta V; Zilio M; Ceccato F; Ciresi A; Daniele A; Pizzolanti G; Campello E; Frigo AC; Giordano C; Scaroni C
    Endocrine; 2018 Oct; 62(1):207-214. PubMed ID: 29980915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pasireotide treatment significantly reduces tumor volume in patients with Cushing's disease: results from a Phase 3 study.
    Lacroix A; Gu F; Schopohl J; Kandra A; Pedroncelli AM; Jin L; Pivonello R
    Pituitary; 2020 Jun; 23(3):203-211. PubMed ID: 31875276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
    Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing's disease.
    Trementino L; Cardinaletti M; Concettoni C; Marcelli G; Polenta B; Spinello M; Boscaro M; Arnaldi G
    Pituitary; 2015 Feb; 18(1):60-7. PubMed ID: 24482099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pasireotide treatment in Cushing's disease: A single tertiary center's experience.
    Şahin S; Karimova G; Özcan ŞG; Durcan E; Özkaya HM; Kadıoğlu P
    Turk J Med Sci; 2022 Apr; 52(2):467-476. PubMed ID: 36161631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cushing's disease: current medical therapies and molecular insights guiding future therapies.
    Lau D; Rutledge C; Aghi MK
    Neurosurg Focus; 2015 Feb; 38(2):E11. PubMed ID: 25639313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.
    Feelders RA; Fleseriu M; Kadioglu P; Bex M; González-Devia D; Boguszewski CL; Yavuz DG; Patino H; Pedroncelli AM; Maamari R; Chattopadhyay A; Biller BMK; Pivonello R
    Front Endocrinol (Lausanne); 2023; 14():1165681. PubMed ID: 37876540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Budget impact of pasireotide for the treatment of Cushing's disease, a rare endocrine disorder associated with considerable comorbidities.
    Truong HL; Nellesen D; Ludlam WH; Neary MP
    J Med Econ; 2014 Apr; 17(4):288-95. PubMed ID: 24617917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term medical treatment of cushing's disease with pasireotide: a review of current evidence and clinical experience.
    Samson SL
    Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):445-50. PubMed ID: 25003365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study.
    Fleseriu M; Iweha C; Salgado L; Mazzuco TL; Campigotto F; Maamari R; Limumpornpetch P
    Front Endocrinol (Lausanne); 2019; 10():436. PubMed ID: 31379734
    [No Abstract]   [Full Text] [Related]  

  • 38. Psychometric evaluation of the Cushing's Quality-of-Life questionnaire.
    Nelson LM; Forsythe A; McLeod L; Pulgar S; Maldonado M; Coles T; Zhang Y; Webb SM; Badia X
    Patient; 2013; 6(2):113-24. PubMed ID: 23575965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease.
    van der Pas R; de Bruin C; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; de Jong FH; van der Lely AJ; de Herder WW; Webb SM; Lamberts SW; Hofland LJ; Feelders RA
    Pituitary; 2013 Dec; 16(4):536-44. PubMed ID: 23225121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective long-term treatment of Cushing's disease with pasireotide: a case report.
    Lu L; Duan L; Jin Z; Lu Z; Gu F
    Endocr Pract; 2013; 19(4):e92-6. PubMed ID: 23512383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.